期刊文献+

非顺应球囊后扩张对置入药物洗脱支架预后的影响 被引量:2

Clinical outcomes of postdilatation with non-compliant balloons following implantation of drug-eluting stents
在线阅读 下载PDF
导出
摘要 目的评估使用非顺应性球囊后扩张对经置入药物洗脱支架冠状动脉粥样硬化性心脏病(以下简称冠心病)患者的疗效。方法回顾性分析2011年1月至2011年5月共356例行药物洗脱支架植入且使用非顺应性球囊后扩张的患者,采用倾向性评分抽取同期356例行药物洗脱支架植入术而未后扩张的患者与之1∶1匹配。结果 2组在年龄、性别、临床表现、主要危险因素及冠状动脉病变特征方面比较,差异无统计学意义(P>0.05),具有可比性。平均随访时间18个月,后扩张组主要不良心血管事件(major adverse cardiac events,MACE)明显低于未后扩张组(10.1%vs 15.7%,P=0.020),主要是靶血管重建(6.2%vs10.7%,P=0.010)、支架内血栓(1.1%vs 3.7%,P=0.030)发生率比较,差异有统计学意义(P<0.05),而心肌梗死(3.9%vs4.6%,P=0.700)、死亡(1.1%vs 1.7%,P=0.760)比较,差异没有统计学意义。结论冠心病患者置入药物洗脱支架后使用非顺应性球囊后扩张安全,可改善患者的临床预后。 Objective To assess the clinical effects of postdilatation with non-compliant balloons following implantation of drug-eluting stents(DES) in patients with coronary artery disease. Methods From January 2011 to July 2011, 356 consecutive patients underwent postdilatation with non-compliant balloons following implantation of DES at Beijing Anzhen Hospital, Capital Medical University. Via propensity score methodology, these patients were matched with 1 group of 356 patients who underwent DES without postdilatation during the same period. Results The two groups were similar for age, sex, clinical presentation, main risk factors and the features of coronary artery lesions. At 18-month follow-up incidence of major adverse cardiac events(MACE) was 10. 1% in the postdilatation treatment group and 15.7% in routine un-postdilatation group(P=0. 020), with a significant difference in target vessel revascularization and stent thrombosis(6. 2% vs 10. 7%, P=0. 010; and 1. 1% vs 3. 7%, P=0. 030, respectively). There were no statistical differences in myocardial infarction(AMI) and death rates in the two groups(3. 9% vs 4. 6%, P=0. 700;1. 7% vs 1. 3%, P=0. 229; and 1. 1% vs 1. 7%, P=0. 760, respectively). Conclusion Postdilatation after DES implantation in patients with coronary artery disease is safe and associated improved clinical outcomes.
出处 《首都医科大学学报》 CAS 北大核心 2015年第2期299-302,共4页 Journal of Capital Medical University
基金 国家临床重点专科建设项目 北京市卫生系统高层次卫生技术人才队伍建设专项(2011-1-5) 北京市医院管理局临床医学发展专项(ZYLX201303)~~
关键词 冠状动脉疾病 药物洗脱支架 后扩张 coronary artery disease drug-eluting stents postdilatation
作者简介 Corresponding author, E-mail : azzyj12@163.com
  • 相关文献

参考文献4

二级参考文献29

  • 1CHANCE研究组.无保护左主干病变支架置入术预后及影响因素的分析——中国无保护左主干病变支架置入术注册(CHANCE)研究[J].中华心血管病杂志,2005,33(3):210-215. 被引量:19
  • 2Eric L Eisenstein, DBA,Kevin J. Anstrom, PhD,David F. Kong, MD,Linda K. Shaw, MS,Robert H. Tuttle, MSPH,Daniel B. Mark, MD, MPH,Judith M. Kramer, MD, MS,Robert A. Harrington, MD,David B. Matchar, MD,David E. Kandzari, MD 1,Eric D. Peterson, MD, MPH,Kevin A. Schulman, MD,Robert M. Califf, MD,李呈亿(译),David E. Kandzari, MD.氯吡格雷的使用与药物洗脱支架植入后远期临床结果[J].美国医学会杂志(中文版),2007,26(3):131-139. 被引量:59
  • 3Hof{mann R,Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in - stent restenosis ~ a steral intravasculal ul- trasond study[J]. Circulation, 1996,94 : 1247 - 1254.
  • 4Harald S, RQbert Z, Thomas CW. Effects of pioglitazone on endothelial function , insulin sensitivity, and glucose control in subjects with coronary artery disease and new- onset type 2 diabetes[J]. Diabetes Care,2006,29(5) :1039 - 1045.
  • 5Tao L, Liu HR, Gao E, et al. Rosiglitazone improves endothe- lial function in rabbits with hypercholesterolemia by reducing oxidative stress and preserving NO/cGMP signaling[J]. Acad Emerg Med,2003,10(5) :4- 5.
  • 6Law RE, Goetze S, Xi XP, et al. Expression and funtion of PPAR gamma in rat and human vascular smooth muscle cells [J]. Circulation,2000,101(11) : 1311 - 1318.
  • 7Diods ST, Bruemmer D, Dilley R J, et al. Inhibitory activity of clinical thiazolidinesione peroxisome proliferator activating receptorgamma ligands toward internal mammary artery, and saphenous vein smooth muscle cell proliferation[J]. Circula- tion, 2003,107 : 2548 - 2550.
  • 8Takagi T, Okura H, Kobayashi Y, et al. A Prospective, Mul ticenter,Randomized Trial to Assess Efficacy of Pioglitazone on In - Stent Neointomal Suppression in Type 2 Diabetes. POPPS(Prevention of In - Stent Neointimal Proliferation by Pioglitazone St udy) [J]. J ACC Cardiovasc Interv, 2009,2 : 532 - 533.
  • 9Pfisterer M, Brunner La Rocca H P, Buser P T, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents [ J ]. J Am Coil Cardiol, 2006,48(12) :2584-2591.
  • 10Mauri L, Hsieh W H, Massaro J M, et al. Stent throm- bosis in randomized clinical trials of drug-eluting stents [J]. N Engl J Med, 2007,356(10):1020-1029.

共引文献578

同被引文献29

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部